Evidence map›Paper›PMID 28446909›Full record

ReviewFrontiers in immunology2017

Clinical Evidence for the Microbiome in Inflammatory Diseases.

Ann E Slingerland, Zaker Schwabkey, Diana H Wiesnoski, Robert R Jenq

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Ethanol Extract ofMarine drugs · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Potential role ofWorld journal of diabetes · 2022
    Review
  10. Article
  11. Review
  12. Frontiers in pharmacology · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Treg Enhancing Therapies to Treat Autoimmune Diseases.International journal of molecular sciences · 2020
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ann E SlingerlandImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zaker SchwabkeyDepartment of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Diana H WiesnoskiDepartment of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert R JenqDepartment of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

TRANSLATIONAL AND ANALYTICAL CHEMISTRY COREP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PETER W PISTERS · 1985 to 2026
$279.3M
Protecting colonic mucus to mitigate acute intestinal graft-versus-host diseaseR01HL124112 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JENQ, ROBERT · 2015 to 2024
$6.8M
NHLBI NIH HHS R01 HL124112
6 · The paper itself

Abstract

Clinical evidence is accumulating for a role of the microbiome in contributing to or modulating severity of inflammatory diseases. These studies can be organized by various organ systems involved, as well as type of study approach utilized, whether investigators compared the microbiome of cases versus controls, followed patients longitudinally, or intervened with antibiotics, prebiotics, or bacterial introduction. In this review, we summarize the clinical evidence supporting the microbiome as an important mechanism in the onset and maintenance of inflammation.

Indexed as

autoimmune diseasesbacteriainflammationmicrobiomemicrobiota

Identifiers

PMID28446909
PMCPMC5388779

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.